Insider Selling: Stryker Co. (NYSE:SYK) VP Sells 2,121 Shares of Stock

Stryker Co. (NYSE:SYK) VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $370.00, for a total transaction of $784,770.00. Following the sale, the vice president now owns 10,042 shares of the company’s stock, valued at $3,715,540. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

M Kathryn Fink also recently made the following trade(s):

• On Tuesday, September 17th, M Kathryn Fink sold 7,347 shares of Stryker stock. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06.

Stryker Trading Down 2.1 %

Shares of SYK opened at $364.00 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68 and a quick ratio of 0.95. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $374.63. The stock has a market cap of $138.71 billion, a PE ratio of 41.55, a P/E/G ratio of 2.87 and a beta of 0.91. The stock’s 50-day moving average is $343.60 and its two-hundred day moving average is $342.61.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.79 by $0.02. The firm had revenue of $5.42 billion during the quarter, compared to analysts’ expectations of $5.40 billion. Stryker had a return on equity of 22.89% and a net margin of 16.12%. Stryker’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.54 EPS. Equities analysts forecast that Stryker Co. will post 12 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend is Monday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.53%.

Wall Street Analyst Weigh In

SYK has been the subject of several analyst reports. Evercore ISI cut their price target on Stryker from $370.00 to $365.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Wolfe Research initiated coverage on Stryker in a research note on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 price target on the stock. Stifel Nicolaus lowered their price target on Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Piper Sandler reiterated an “overweight” rating and set a $380.00 price objective on shares of Stryker in a report on Tuesday, September 10th. Finally, The Goldman Sachs Group began coverage on shares of Stryker in a report on Thursday, May 30th. They issued a “neutral” rating and a $372.00 target price for the company. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $378.58.

Hedge Funds Weigh In On Stryker

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SYK. Global Assets Advisory LLC purchased a new position in Stryker in the first quarter valued at about $341,049,000. JPMorgan Chase & Co. boosted its stake in shares of Stryker by 10.4% during the 1st quarter. JPMorgan Chase & Co. now owns 8,651,403 shares of the medical technology company’s stock valued at $3,096,078,000 after buying an additional 813,311 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Stryker by 5.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,541,845 shares of the medical technology company’s stock worth $3,755,782,000 after buying an additional 642,178 shares in the last quarter. 1832 Asset Management L.P. raised its holdings in Stryker by 146.9% in the first quarter. 1832 Asset Management L.P. now owns 878,669 shares of the medical technology company’s stock valued at $314,449,000 after acquiring an additional 522,817 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in Stryker by 287.6% during the 2nd quarter. American Century Companies Inc. now owns 505,608 shares of the medical technology company’s stock valued at $172,033,000 after acquiring an additional 375,166 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.